Calliditas’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

Calliditas is a pharmaceutical company that develops and commercializes therapeutics for the treatment of inflammatory kidney diseases. Read more

Renee Aguiar-Lucander's photo - CEO of Calliditas

CEO

Renee Aguiar-Lucander

CEO Approval Rating

90/100

Founded:

2004

Status:

PublicNASDAQCALT

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Diamyd Medical is one of Calliditas's top competitors. Diamyd Medical was founded in 1996, and its headquarters is in Stockholm, Stockholms län. Like Calliditas, Diamyd Medical also works within the Biotechnology sector. Diamyd Medical has 39 more employees than Calliditas.

TriSalus Life Sciences is Calliditas's #2 rival. TriSalus Life Sciences was founded in null in , . TriSalus Life Sciences competes in the field. TriSalus Life Sciences generates $ less revenue than Calliditas.

Soligenix is a top competitor of Calliditas. Soligenix is a Public company that was founded in Princeton, New Jersey in 1987. Soligenix competes in the Pharmaceuticals industry. Soligenix has 9 fewer employees vs. Calliditas.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Apple a competitor of Calliditas?

Quarterly and Annual Revenue

Coming soon for Calliditas!

Annual Revenue

$ < 1M

Calliditas's revenue is the ranked 3rd among it's top 10 competitors. The top 10 competitors average 1.5M.

Acquisitions

No recent acquisitions found related to Calliditas

Calliditas Funding History

$81M

Since Calliditas was founded in 2004, it has participated in 1 round of funding. In total Calliditas has raised $81.0M. Calliditas' funding round was on May 2020 for a total of $81.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

IPO
May 2020
$81M
-

Total Funding: $81M

Since Calliditas was founded in 2004, it has participated in 1 round of funding. In total Calliditas has raised $81.0M. Calliditas' funding round was on May 2020 for a total of $81.0M

Investments

No recent investments found related to Calliditas

Calliditas News

August 13, 2020BioSpace

Interim Report Q2, 2020

"In June we successfully closed a $90m U.S. IPO on NASDAQ, which including the greenshoe that was exe... See more »
July 2, 2020BioSpace

Exercise of Over-allotment Option and End of the Stabilization Period - July 02, 2020

Citigroup Global Markets Inc., in its capacity as Joint Global Coordinator, notifies that the stabili... See more »
June 30, 2020FinanzNachrichten

Number of Shares and Votes in Calliditas Therapeutics

STOCKHOLM, June 30, 2020 /PRNewswire/ -- During June, Calliditas Therapeutics AB (publ) has issued 9,... See more »
June 30, 2020Benzinga

Why Calliditas Therapeutics Stock Trading Higher Today

Calliditas Therapeutics (NASDAQ: CALT) shares are trading higher on Tuesday after Jefferies initiated... See more »
June 25, 2020FinanzNachrichten

Bulletin From the Annual General Meeting of Calliditas Therapeutics AB (publ)

STOCKHOLM, June 25, 2020 /PRNewswire/ -- The following resolutions were passed at Calliditas Therapeu... See more »
June 22, 2020Pharamceutical Technology

Calliditas IPO raises $90m to support rare disease pipeline

Sweden-based biotech Calliditas Therapeutics has closed its initial public offering (IPO) on the Nasd... See more »

Calliditas Press Releases

March 30, 2020PR Newswire

Calliditas Moves its Annual General Meeting 2020 to June 25

/PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that due to the rece... See more »
March 3, 2020PR Newswire

Bulletin From the Extraordinary General Meeting of Calliditas Therapeutics AB (publ)

STOCKHOLM, March 3, 2020 /PRNewswire/ -- As part of the preparations for a potential offering of Amer... See more »
November 14, 2019centralcharts

Interim Report Q3, 2019

Interim Report Q3, 2019 Positive Regulatory Outcome - Enhanced study design PR Newswire STOCKHOLM, No... See more »
November 4, 2019StreetInsider

Calliditas Therapeutics Capital Markets Day Today November 4

STOCKHOLM, Nov. 4, 2019 /PRNewswire/ -- Calliditas Therapeutics ("Calliditas") today hosts a Capital ... See more »
October 1, 2019StreetInsider

Positive Interactions With EMA Provide Route to Conditional Marketing Authorization of Lead Candidate Nefecon

STOCKHOLM, Oct. 1, 2019 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announ... See more »
August 15, 2019CentralCharts

Interim Report Q2, 2019

This second quarter of 2019 was very busy and exciting as we concluded a USD 121 million (SEK 1.1 bil... See more »

Headquarters

Kungsbron 1

Stockholm, Stockholms län10465

46-8-411-3005

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Calliditas is a pharmaceutical company that develops and commercializes therapeutics for the treatment of inflammatory kidney diseases. Calliditas was founded in 2004. Calliditas' headquarters is located in Stockholm, Stockholms län, SE 10465. It has ...

CEO

Calliditas's CEO, Renee Aguiar-Lucander, currently has an approval rating of 90%. Calliditas's primary competitors are Diamyd Medical, TriSalus Life Sciences & Soligenix.

Website

calliditas.se

Frequently Asked Questions about Calliditas

  1. When was Calliditas founded?

    Calliditas was founded in 2004
  2. Who is Calliditas's CEO?

    Calliditas's CEO is Renee Aguiar-Lucander
  3. How much revenue does Calliditas generate?

    Calliditas generates $ < 1M in revenue
  4. How much funding does Calliditas have?

    Calliditas has historically raised $81M in funding
  1. Where is Calliditas's headquarters?

    Calliditas's headquarters is in Stockholm Stockholms län, SE
  2. How many employees does Calliditas have?

    Calliditas has 24 employees
  3. What sector does Calliditas operate in?

    Calliditas is in Biotechnology
  4. Who are Calliditas's competitors?

    Calliditas's top competitors are Diamyd Medical, TriSalus Life Sciences, Soligenix